Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2020-06-24 | 2020-12-17 | 118769 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2020-07-29 | 2020-12-17 | 121334 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2020-07-29 | 2020-12-17 | 121337 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2020-09-09 | 2020-12-17 | 123957 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2020-10-07 | 2020-12-17 | 125815 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-04-01 | 2022-04-29 | 157701 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-06-06 | 2022-07-11 | 162083 |
| APO-OLANZAPINE | 10MG | TABLET | Resolved | 2022-10-07 | 2022-12-05 | 171422 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-10-17 | 2022-12-05 | 171886 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2022-10-28 | 2022-12-09 | 172901 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-01-26 | 2023-02-02 | 182367 |
| APO-OLANZAPINE | 10MG | TABLET | Resolved | 2023-02-09 | 2023-06-02 | 184083 |
| APO-OLANZAPINE | 20MG | TABLET | Resolved | 2023-02-09 | 2023-06-02 | 184097 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-05-06 | 2023-06-02 | 191874 |
| APO-OLANZAPINE | 10MG | TABLET | Resolved | 2023-07-13 | 2023-09-15 | 198518 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-07-27 | 2023-09-28 | 200180 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2023-08-18 | 2023-09-28 | 202403 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2023-11-06 | 2024-03-01 | 209363 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2025-08-28 | 2025-09-19 | 266084 |
| APO-OLANZAPINE ODT | 20MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2017-06-13 | 2017-07-31 | 12689 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |